Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03455075 · ClinicalTrials.gov registry record · Phase 2
Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men
A Phase 2 study, sponsored by Premier Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT03455075 is a Phase 2 study that has completed, run by Premier Research. The registered enrollment target is 92 participants.
The verdict
NCT03455075, a Phase 2 study, has completed, sponsored by Premier Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a Phase IIa multicenter, double-blind, placebo-controlled study in healthy men to evaluate the spermatogenesis suppression after oral administration of Dimethandrolone Undecanoate (DMAU) alone or with Levonorgestrel (LNG) for 12 weeks versus placebo alone.
Interventions
- DRUG Placebo oral capsule
- DRUG Dimethandrolone-Undecanoate
- DRUG Levonorgestrel 0.03 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-04-16 |
| Est. Completion | 2020-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03455075
The ClinicalTrials.gov registry entry for NCT03455075 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Premier Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT03455075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03455075 about?
NCT03455075 is a clinical study titled "Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men". This is a Phase IIa multicenter, double-blind, placebo-controlled study in healthy men to evaluate the spermatogenesis suppression after oral administration of Dimethandrolone Undecanoate (DMAU) alone or with Levonorgestrel (LNG) for 12 weeks versus placebo alone.
What is the current status of trial NCT03455075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2018-04-16. Estimated completion is 2020-03-05.
What interventions are being tested in trial NCT03455075?
The interventions under investigation include: Placebo oral capsule (DRUG), Dimethandrolone-Undecanoate (DRUG), Levonorgestrel 0.03 MG (DRUG).
Who is sponsoring clinical trial NCT03455075?
This trial is sponsored by Premier Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.